ATRX

Across TCGA pan-cancer cohorts, ATRX mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATRX data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATRX mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ATRX expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, HNSC, and CCRCC are the cancer types where ATRX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.819	0.426	<.001	48	view →
HNSC	DFS	Quartile	All	0.333	1.000	.014	21	view →
CCRCC	DFS	Tertile	II,III,IV	1.000	0.270	.013	14	view →
UCEC	OS	Tertile	All	0.918	1.000	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ATRX–LUAD (OS)

Open the LUAD breakdown →